Minisymposium: Biomarkers in Drug Discovery – How to Predict for Success in the Clinic


Co-arrangement between SciLifeLab Drug Discovery and Development platform and AstraZeneca

Biomarkers have influence on understanding of disease mechanism, optimize the chance for successful patients’ selection and outcomes of clinical trials and thus may contribute to minimizing cost of a drug development. In drug discovery, the accompanying discovery of potential biomarkers and the subsequent development as tools to identify patients that can benefit from treatment and to demonstrate a pharmacological response to the exploratory drug are therefore of increasing importance. In this minisymposium, we gather international academic and industrial experts to review state-of-the-art and new initiatives. Please, take the chance to discuss your own project with the speakers during the day.

Most welcome!
The organizing committee

Vendela Parrow, Pawel Baranczewski, Rebecka Klintenberg & Kristian Sandberg, SciLifeLab Drug Discovery and Development Platform; Anna Sandström, AstraZeneca

 

Preliminary Programme

10:00 Introduction

Kristian Sandberg, SciLifeLab/DDD and Anna Sandström, AstraZeneca

 

10:15 Biomarkers in 21st Century Drug Development

Virginia Byers Kraus, MD, PhD (Durham, North Carolina, US)

 

11:00 Transforming Drug Research and Development with Genomics’

Carolina Haefliger, MD, AstraZeneca VP, Head of CVRM Precision Medicine

 

11:30 Turning a biomarker candidate into a diagnostic for clinical use

Joachim Reischl, AstraZeneca VP, Head of Policy, Portfolio & Externalisation

 

12:00 Lunch and mingle

 

13:00 Rigging diagnostics for new predictive biomarkers – the Genomic Medicine Sweden initiative

Johan Botling, MD, PhD, Uppsala University

 

13:30 Truly Translational – helping the small to think big. Biomarker strategies for SME’s

Karin von Wachenfeldt, PhD, CEO Truly Translational Sweden AB

 

14:00 SCAN-B: transcriptome profiling of early breast cancer for identification of patients that may benefit from treatment

Åke Borg, PhD, Lund University

 

14:30 Coffee and mingle

 

15:00 Biomarkers in the development of KAND567 in acute myocardial infarction

Niclas Brynne, PhD, Chief Development officer at Kancera

 

15:30 Panel discussion and concluding remarks

 

 

Registration

This Event is now fully booked.